Annual Reports in Medicinal ChemistryEdited by
- Annette Doherty, Pfizer Global R&D, Sandwich Laboratories, United Kingdom
Annual Reports in Medicinal Chemistry provides timely and critical reviews of important topics in medicinal chemistry together with an emphasis on emerging topics in the biological sciences, which are expected to provide the basis for entirely new future therapies.
Medicinal, pharmaceutical, and organic chemists.
Annual Reports in Medicinal Chemistry
Hardbound, 364 Pages
Published: October 2002
Imprint: Academic Press
"This series is one of the very few annual publications which justify the title of an absolute must for the pharmacologist, chemist, or physician who is interested in the chemistry of drug development." ENZYMOLOGIA "This book is strongly recommended for researchers, teachers, students, administratorsin short, anyone whose interests impinge on medicinal chemistry. In view of the work's documented reference value, it is a must for inclusion in the scientist's personal library." JOURNAL OF MEDICINAL CHEMISTRY "All topics are covered in sufficient depth, with extensive references, to allow either the specialist or the novice to be informed of the latest developments in a particular area of medicinal chemistry." JOURNAL OF PHARMACEUTICAL SCIENCES
- I. CENTRAL NERVOUS SYSTEM DISEASESSection Editor: David W. Robertson, Pfizer Global Research & Development, Ann Arbor, MI1. Promise and Progress of Central G-Protein Coupled Receptor Modulators 1 for Obesity Treatments Brian L. Largent, Albert J. Robichaud and Keith J. Miller, Bristol-Myers Squibb Company, Wilmington, Delaware 2. Attention Deficit Hyperactivity Disorder: Pathophysiology and Design of 11 New TreatmentsShelly A. Glase, Larry D. Wise and David W. Robertson, Pfizer Global Research and Development, Ann Arbor, Michigan3. 5-HT2C Receptor Modulators: Progress in Development of 21 New CNS Medicines Larry E. Fitzgerald and Michael D. Ennis, Pharmacia Corporation, Kalamazoo, Michigan4. Emerging Themes in Alzheimer's Disease Research: Paradigm Shift in Drug Discovery 31Todd Morgan, School of Gerontology, University of Southern California, Los Angeles, California and Grant A. Krafft, Acumen Pharmaceuticals, Glenview, IllinoisII. CARDIOVASCULAR AND PULMONARY DISEASESSection Editor: William J. Greenlee, Schering-Plough Research Institute, Kenilworth, New Jersey5. Recent Advances in Pulmonary Hypertension Therapy 41 Russell A. Bialecki, AstraZeneca Pharmaceuticals, Wilmington, Delaware6. Phosphodiesterase 5 Inhibitors 53 Andrew W. Stamford, Schering-Plough Research Institute, Kenilworth, New Jersey7. Antagonists of VLA-4 65 George W. Holland, Ronald J. Biediger, and Peter Vanderslice,Texas Biotechnology Corporation, Houston, Texas8. Purine and Pyrimidine Nucleotide (P2) Receptors 75Kenneth A. Jacobson, Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland 9. Anticoagulants: Inhibitors of the Factor VIIa/ Tissue Factor Pathway 85 Leslie A. Robinson and Eddine M. K. Saiah, Deltagen Research Laboratories, San Diego, CaliforniaIII. CANCER AND INFECTIOUS DISEASESSection Editor: Jacob J. Plattner, Chiron Corporation, Emeryville, California10. The Prospect for Microbial Genomics Providing Novel, Exploitable, 95 Antibacterial Targets Thomas J. Dougherty, Pfizer Global Research & Development, Groton, Connecticut and John F. Barrett, Merck Research Laboratories, Rahway, New Jersey 11. The Chemistry and Biology of Tetracyclines 105 Mark L. Nelson, Paratek Pharmaceuticals, Inc., Boston, Massachusetts 12. Intracellular Signaling Targets for Cancer Chemosensitization 115 Thomas G. Gesner and Stephen D. Harrison, Chiron Corporation, Emeryville, California 13. Emerging Microtubule Stabilizing Agents for Cancer Chemotherapy 125 David C. Myles, Kosan Biosciences, Inc., Hayward, California 14. Antiviral Agents 133 Nicholas A. Meanwell, John F. Kadow and Paul M. Scola, The Bristol-Myers Squibb Pharmaceutical Research Institute Wallingford, Connecticut15. Aerosol Delivery of Antibiotics 149 Peter B. Challoner, Chiron Corporation, Emeryville, CaliforniaIV. IMMUNOLOGY, ENDOCRINOLOGY AND METABOLIC DISEASESSection Editor: William K. Hagmann, Merck Research Laboratories, Rahway, New Jersey16. Therapeutic Applications of Non-peptidic d-Opioid Agonists 159 Graham N. Maw and Donald S. Middleton, Pfizer Global Research and Development, Department of Discovery Chemistry, Sandwich, Kent 17. Selective Glucocorticoid Receptor Modulators 167 Michael J. Coghlan*, Steven W. Elmore, Philip R. Kym and Michael E. Kort, *Eli Lilly and Company, Discovery Chemistry Research & Technologies, DC , Lilly Corporate Center, Indianapolis, Indiana, Abbott Laboratories, Global Pharmaceutical Research and Development, Illinois18. Inhibitors of p38 a MAP Kinase 177 Sarvajit Chakravarty and Sundeep Dugar, Scios Inc. Sunnyvale, CaliforniaV. TOPICS IN BIOLOGYSection Editor: Janet M. Allen, Inpharmatica, London, United Kingdom19. Expanding and Exploring Cellular Pathways for Novel Drug Targets 187Malcolm P. Weir, John P. Overington and Marlon Schwarz, Inpharmatica Ltd., London, 20. Searching for Alzheimer's Disease Therapies In Your Medicine Cabinet: 197 The Epidemiological and Mechanistic Case For NSAIDs and Statins Robert B. Nelson, Pfizer Global Research and Development, Groton, Connecticut21. Matrix Metalloproteinases and the Potential Therapeutic Role for Matrix 209 Metalloproteinase Inhibitors in Chronic Obstructive Pulmonary Disease Kevin M. Bottomley and Maria G. Belvisi, Inpharmatica, London and Respiratory Pharmacology, Cardiothoracic Surgery,Imperial College School of Medicine, National Heart and Lung Institute, London22. Fc Receptor Structure and the Design of Anti-inflammatories: New 217 Therapeutics For Autoimmune Disease. Geoffrey A. Pietersz, Maree S. Powell, Paul A. Ramsland and P. Mark Hogarth, Austin Research Institute, Austin and Repatriation Medical Center, Victoria, Australia23. Tumor classification for tailored cancer therapy 225 Fiona McLaughlin and Nick LaThangue, Prolifix Ltd, Abingdon, Oxon VI. TOPICS IN DRUG DESIGN AND DISCOVERYSection Editor: George L. Trainor, DuPont Pharmaceuticals Company, Wilmington, Delaware24. Advances in the Discovery and Characterization of Ion Channel 237 Modulators: Focus on Potassium Channels Valentin K. Gribkoff and John E. Starrett, Jr., Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut25. Microwave-Assisted Chemistry as a Tool for Drug Discovery 247 Carolyn D. Dzierba and Andrew P. Combs, Bristol-Myers Squibb Co. Experimental Station, Wilmington, Delaware VII. TRENDS AND PERSPECTIVESSection Editor: Annette M. Doherty, Pfizer Global Research & Development, Fresnes Laboratories, Fresnes, France26. To Market, To Market - 2001 257 Patrick Bernardelli, Bernard Gaudillière and Fabrice Vergne, Pfizer Global Research & Development, Fresnes Laboratories, Fresnes, France27. Biosimulation: Dynamic Modeling of Biological Systems 279 Kevin Hall, Rebecca Baillie, and Seth Michelson, Entelos Inc., Menlo Park, CaliforniaCOMPOUND NAME, CODE NUMBER AND SUBJECT INDEX, VOLUME 37 289 CUMULATIVE CHAPTER TITLES KEYWORD INDEX, VOLUMES 1-37 297 CUMULATIVE NCE INTRODUCTION INDEX, 1983-2001 315 CUMULATIVE NCE INTRODUCTION INDEX, 1983-2001, BY INDICATION 331